Lessons from the withdrawal of rofecoxib.

Paul A Dieppe ; Shah Ebrahim ; Richard M Martin ; Peter Jüni ; (2004) Lessons from the withdrawal of rofecoxib. BMJ, 329 (7471). pp. 867-868. ISSN 1468-5833 DOI: 10.1136/bmj.329.7471.867

Copy

Patients would be safer if drug companies disclosed adverse events before licensing

Item Type	Article
Keywords	Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Cyclooxygenase Inhibitors/adverse effects, Drug Approval, Humans, Lactones/adverse effects, Anti-Inflammatory Agents, Non-Steroidal, adverse effects, Cyclooxygenase Inhibitors, adverse effects, Drug Approval, Humans, Lactones, adverse effects
ISI	224566800001
Date Deposited	17 Oct 2011 19:34